ARCHIVES

Phase III Xilonix Study Halted Following Unscheduled Analysis

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI CTEP-Approved Trials For the Month of March

March 28, 2014

Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL

December 27, 2013

Wisconsin Group Takes Lead In Challenging Pain Control Perception

April 21, 1989

Limit On Number Of Surgery Planning Grants Lifted After DCT Board Pressure

March 19, 1982

In Brief: Mauer New AACI President, Steckel Named President-Elect; Prevention Conference Set

January 25, 1980

Cancer Patient Lobby Outlines Agenda For FDA Reform, Seeks Role In Discussion

June 23, 1995